Early data back J&J and AC Immune’s Alzheimer’s jab
pharmaphorum
FEBRUARY 11, 2021
Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a phase 1/2 trial. . ACI-35.030, partnered with Johnson & Johnson, is designed to stimulate the body to generate antibodies against tau protein, one of the factors though to play a role in the development of AD dementia.
Let's personalize your content